Today: 20 May 2026
Browse Category

NASDAQ:GILD 21 December 2025 - 25 February 2026

Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst

Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst

Arcellx shares jumped 77.6% to $113.84 after Gilead Sciences agreed to buy the company for $115 per share in cash plus a contingent value right tied to anito-cel sales. The deal came as U.S. stocks fell on new 15% global tariffs announced by President Trump. Gilead shares slipped 0.6%. Investors are watching the FDA’s Dec. 23, 2026 review deadline for anito-cel, a CAR-T therapy for multiple myeloma.
23 February 2026
··
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Gilead (GILD) stock slips as Yeztugo outlook keeps traders on edge

Gilead (GILD) stock slips as Yeztugo outlook keeps traders on edge

Gilead Sciences shares fell 1.8% to $152.94 Thursday, giving back gains after its 2026 outlook and Yeztugo sales forecast missed some analyst expectations. The company projected $800 million in 2026 Yeztugo sales, below consensus. Fourth-quarter revenue rose 5% to $7.9 billion. Several brokerages raised price targets despite policy and pricing concerns.
12 February 2026
·
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead stock hits fresh 52-week high as Wall Street lifts targets into earnings

Gilead Sciences shares rose 1.8% to $140.24 Tuesday afternoon, hitting a 12-month high of $141.69 earlier in the session. Citi, Truist, and BMO raised price targets following upbeat analyst notes and strong momentum for the company’s HIV prevention drug Yeztugo. Investors await early February results and Gilead’s earnings, expected around Feb. 10.
27 January 2026
···
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
··
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead Sciences shares rose 3.65% to $135.93 after Phase 3 trial results showed Trodelvy plus Keytruda cut the risk of breast cancer progression or death by 35% versus Keytruda and chemotherapy. The company has submitted regulatory filings in the U.S. and Europe. CEO Daniel O’Day plans to sell up to $15.6 million in shares. Investors await Gilead’s earnings report on Feb. 10.
24 January 2026
·
Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead Sciences shares slipped 0.2% to $124.68 Tuesday, outperforming a broader market drop. Bernstein reiterated its Outperform rating and $135 target, citing Yeztugo as a key 2026 driver. Florida announced steep cuts to its AIDS Drug Assistance Program, drawing criticism from advocates and raising concerns over HIV drug access.
20 January 2026
··
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit

Gilead Sciences shares closed up 0.15% at $124.91 on Monday after Bernstein said new Medicaid drug-pricing rules would have limited impact on its HIV drug Biktarvy. Bernstein estimated less than $200 million in 2026 revenue impact for older HIV drugs Genvoya and Odefsey. Investors await more details from the Trump administration’s pricing rollout and Gilead’s update at the J.P. Morgan Healthcare Conference in January.
30 December 2025
·
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025

Gilead Sciences shares closed up 0.83% at $125.19 on Dec. 23, 2025, then held steady after hours. The company announced it will exclusively license Assembly Biosciences’ herpes drug candidates, expanding its antiviral pipeline. U.S. markets will close early on Dec. 24, with thin trading expected. Investors are watching for headlines and Gilead’s upcoming J.P. Morgan Healthcare Conference appearance.
24 December 2025
·
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open

Gilead Sciences closed Monday at $124.16, down 0.10%, and edged up to $124.35 after hours. The company announced it will exclusively license Assembly Biosciences’ herpes simplex virus drug candidates, paying $35 million upfront with potential milestones up to $330 million. Volume for the session was about 6.52 million shares. Market cap stood near $154 billion.
23 December 2025
·
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences said Monday it will license Assembly Biosciences’ investigational herpes simplex virus programs, including two oral candidates, for a $35 million payment. The move expands Gilead’s antiviral pipeline days after it joined a Trump administration drug-pricing deal. Shares traded around $123–$124, slightly lower on the day. No new HSV therapies have been approved in the U.S. or Europe for over 25 years.
22 December 2025
·
Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences (GILD) Stock: What to Know Before the Market Opens on December 22, 2025

Gilead Sciences shares traded near $124.29, up 2.35% premarket Monday, after the company signed a three-year U.S. drug-pricing agreement and reported late-stage HIV pipeline progress. The deal includes discounts on key medicines and a direct-to-patient program, with Gilead expecting a manageable financial impact. Shares remain close to their 52-week high of $128.70.
22 December 2025
·
Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences (GILD) Stock Week-Ahead Outlook: Pricing Deal Shockwave, HIV Pipeline Momentum, and Key Catalysts for Dec 22–26, 2025

Gilead Sciences shares closed near $124.29 ahead of Christmas week as investors reacted to a new U.S. drug-pricing deal announced Dec. 19 and positive late-stage HIV trial results. The company expects manageable financial impact from Medicaid discounts and new pricing commitments. Gilead reported its investigational HIV regimen matched Biktarvy in Phase 3 results, with no major safety issues.
21 December 2025
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
1 2

Stock Market Today

  • Webjet Shares Drop to Record Low as Travel Bookings Decline and Virgin Australia Cuts Commissions
    May 19, 2026, 11:16 PM EDT. Webjet (ASX: WEB) shares hit a record low following a sharp fall in travel bookings amid the Middle East war. The online travel agency reported underlying earnings before interest, tax, depreciation and amortisation (EBITDA) of $28.1 million for the year to March 31, a decline driven by reduced flight sales. Virgin Australia's decision to cut commission rates further pressures Webjet's future earnings. The company noted the first seven weeks of the new financial year have been even more challenging, reflecting ongoing travel industry uncertainties and geopolitical risks impacting consumer demand for flights.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Go toTop